Zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, is approved for several therapeutic indications. The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug has an added benefit compared with the appropriate comparator therapy for adult patients with chronic lymphocytic leukaemia (CLL) after a relapse or in the case of refractory disease, i. e. disease that has not responded to the previous treatment.
Trastuzumab Deruxtecan Shows Benefits in HER2-Low Breast Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Automobili Lamborghini closes the first nine months of 2023 with an operating result exceeding the fiscal year 2022
thenewsmarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenewsmarket.com Daily Mail and Mail on Sunday newspapers.